Yu HA, Goldberg SB, Le X, Piotrowska Z, et al. Biomarker-Directed Phase II Platform Study in Patients With EGFR Sensitizing Mutation-Positive Advanced/Metastatic Non-Small Cell Lung Cancer Whose Disease Has Progressed on First-Line Osimertinib Therapy (ORCHARD). Clin Lung Cancer 2021 Jun 25. pii: S1525-7304(21)00157.
PMID: 34389237